Cargando…
Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades
For pharmaceutical companies, it is essential to define their long-term corporate strategy. This especially involves the pipeline progress of pharmaceuticals and portfolio management. The objective of this study was to give a broad overview of study durations of the clinical trials from the top 30 p...
Autores principales: | Büssgen, Melanie, Büssgen, Marcel A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540351/ https://www.ncbi.nlm.nih.gov/pubmed/37770995 http://dx.doi.org/10.1186/s40545-023-00612-6 |
Ejemplares similares
-
Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades
por: Büssgen, Melanie, et al.
Publicado: (2022) -
Indication-wide drug pricing: Insights from the pharma market
por: Siegmeier, Florian, et al.
Publicado: (2022) -
Does health technology assessment compromise access to pharmaceuticals?
por: Büssgen, Melanie, et al.
Publicado: (2022) -
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023) -
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
por: Özdemir, Dilay, et al.
Publicado: (2023)